CanSino Gets China's First COVID-19 Vaccine Patent

CanSino Gets China's First COVID-19 Vaccine Patent

CanSino Biologics Inc CASBF has become the first company to secure a patent for its COVID-19 vaccine in China, Reuters reported Sunday.

What Happened

The Tianjin, China-based company's patent for its Ad5-nCOV vaccine against COVID-19 stands approved by China’s National Intellectual Property Administration as of August 11, according to Reuters.

Saudi Arabia announced last month plans to test the CanSino vaccine in Phase 3 trials. The company is reportedly also negotiating with Brazil, Chile, and Russia to launch similar trials.

Why It Matters

In May, the Chinese vaccine maker’s Phase 2 clinical trial application was approved by Canadian federal health regulator. 

Multiple vaccine candidates from companies such as Pfizer Inc PFE and its partner BioNTech SE BNTX, Moderna Inc MRNA, Johnson and Johnson JNJ are in late-stage trials or nearing them. 

The U.K. government will support the Phase 3 trial of Novavax, Inc’s NVAX vaccine in a supply deal reached with the company.

AstraZeneca plc AZN has inked a deal with the governments of Mexico and Argentina for supply of its potential COVID-19 vaccine to Latin American countries, excluding Brazil.

Russia claims its “Sputnik V” vaccine is available for immediate use, but the absence of a Phase 3 trial is leading to a division among experts on safety.

Price Action 

CanSino OTC shares closed nearly 2.6% lower at $25.36 on Friday.

Photo courtesy: National Cancer Institute via Wikimedia

Posted In: ChinaCoronavirusCoronavirus VaccineCovid-19ReutersVaccinesBiotechNewsHealth CareMediaGeneral